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Abstract
Background: Pirin (PIR) is a highly conserved nuclear protein originally isolated as an interactor of NFI/CTF1
transcription/replication factor. It is a member of the functionally diverse cupin superfamily and its activity has
been linked to different biological and molecular processes, such as regulation of transcription, apoptosis, stress
response and enzymatic processes. Although its precise role in these functions has not yet been defined, PIR
expression is known to be deregulated in several human malignancies.
Results: We performed immunohistochemical analysis of PIR expression in primary samples from normal human
tissues and tumors and identified a dislocation of PIR to the cytoplasm in a subset of melanomas, and a positive
correlation between cytoplasmic PIR levels and melanoma progression. PIR localization was subsequently analyzed
in vitro in melanoma cell lines through a high content immunofluorescence based approach (ImmunoCell-Array).
Conclusions: The high consistency between in vivo and in vitro results obtained by immunohistochemistry and
ImmunoCell-Array provides a validation of the potential of ImmunoCell-Array technology for the rapid screening of
putative biological markers, and suggests that cytoplasmic localization of PIR may represent a characteristic of
melanoma progression.
Background
Pirin (PIR) is a highly conserved protein originally
described as an interactor of the nuclear I/CCAAT box
transcription factor (NFI/CTF1) [1]. Orthologs have
been found throughout evolution in mammals, plants,
fungi and prokaryotic organisms [1]. On the basis of its
structural and biochemical characterization, PIR was
assigned to the cupin superfamily of proteins [2], which
is among the most functionally diverse described to
date. The crystal structure of human PIR, supported by
biochemical studies, revealed that it possesses querceti-
nase enzymatic activity responsible for the degradation
of the Quercetin flavonoid [3], which is involved in the
regulation of many cellular processes as antioxidant
[4,5], protein kinase inhibitor [6] and regulator of
transcription [7]. PIR has, in fact, been described as a
putative transcriptional regulator. Besides its original
identification as an interactor of NFI/CTF1 [1], PIR also
interacts with the proto-oncoprotein Bcl-3 [8], which
modulates the activity of NF-B/Rel transcription fac-
tors [9,10].
Other reports suggest an involvement of PIR in the
regulation of apoptosis in plants and in human models.
Increased levels of PIR mRNA were associated to death-
inducing conditions such as camptothecin-induced pro-
grammed cell death in tomato [11] or chronic cigarette
smoke in human bronchial epithelial cells [12]. On the
other hand, prokaryotic orthologs of PIR were found to
be involved in stress response, but not in cell death [13].
Several studies suggest that a deregulation of PIR
expression may be associated to tumor progression
[14-16]. We previously found that PIR mRNA expres-
sion is silenced by the acute myeloid leukemia (AML)-
associated fusion proteins PML/RARa and AML1/ETO
both in cellular models and in primary blasts form AML
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patients [17]. We, therefore, investigated if PIR expres-
sion levels are modulated in other types of malignancies
and found that PIR is expressed at high levels in a sub-
set of melanomas. Here we demonstrate that PIR is
delocalized from the nucleus to the cytoplasm in a pro-
portion of primary melanomas, and that cytoplasmic
localization correlates with disease progression. We
further demonstrate that this pattern of PIR delocaliza-
tion is maintained in vitro in primary and established
melanoma cell lines using a high density ImmunoCell-
Array (ICA) approach [18,19], which allows for simulta-
neous analysis of protein levels and localization in mul-
tiple cell lines. Our results show that cytoplasmic
delocalization of PIR is characteristic of a subset of
advanced stage melanomas, and validates the efficacy of
ICA for multiplexed immunofluorescence analysis of
target proteins in different cellular models.
Results and Discussion
To investigate if PIR deregulation was a common feature
in human malignancies other than AML, we studied PIR
protein expression in a collection of normal and trans-
formed human tissues by immunohistochemistry (IHC)
using a rabbit polyclonal antibody raised against human
PIR. In accordance to previous data [1], PIR protein was
expressed at very low levels in most tissues (data not
shown). The sole exception was represented by a sub-
group of samples deriving from nevi, primary and meta-
static melanomas. We, therefore, analyzed by IHC a
melanoma-specific tissue microarray (TMA), containing
surgical samples from 117 primary melanomas and 57
metastatic melanomas. Strikingly, PIR localization was
not homogeneous across all samples. Previous studies
described PIR as a nuclear protein, predominantly loca-
lized within sub-nuclear dot-like structures [1]. Concor-
dantly, normal melanocytes from healthy tissue sections
showed PIR expression exclusively in the nucleus (Figure
1a), whereas melanoma samples expressing PIR showed a
varied pattern of protein localization, ranging from
nuclear to prevalently cytoplasmic (Figure 1b-e). Interest-
ingly, cytoplasmic PIR appeared to correlate with mela-
noma progression (Figure 1f): in Radial Growth Phase
(RGP) melanoma, which represents an early step of mela-
noma progression, PIR is localized in the nucleus in 50%
of the cases, and shifts to the cytoplasm in 40% of cases,
the remaining 10% having both nuclear and cytoplasmic
expression. In more infiltrating Vertical Growth Phase
(VGP) melanomas, the percentage of cases with nuclear
PIR is of 11,5%, whereas cytoplasmic localization is
detectable in 84,6% of cases and only a minor fraction
(3,8%) has both nuclear and cytoplasmic staining. Finally,
all tested metastatic melanomas express PIR in the cyto-
plasm, with some degree of nuclear staining in 12,5% of
the cases only.
In summary, we found a shift of PIR sub-cellular loca-
lization from the nucleus to the cytoplasm in a relevant
subset of melanoma samples; furthermore, the propor-
tion of cases displaying cytoplasmic PIR increases with
melanoma progression. The cytoplasmic localization is
less frequent in RGP than in advanced VGP melanoma
and, in the latter, the percentage of cases bearing cyto-
plasmic PIR is comparable to that of metastatic mela-
noma, where there is virtually no PIR in the nucleus.
These data suggest that the shift of PIR localization
from nucleus to cytoplasm may be a marker of mela-
noma progression.
Data obtained by IHC analysis of primary tumours are
highly informative and reliable as to protein expression
and localization in vivo. However, to further explore the
relevance of PIR delocalization during progression of
the malignancy, we decided to switch to primary cul-
tures and cell lines derived from melanomas. In order to
assess if PIR localization in in vitro experimental model
systems is representative of the pattern identified in
vivo, we analyzed PIR expression in 17 primary or estab-
lished melanoma cell lines by means of a slightly modi-
fied ICA method [18,19] to perform simultaneous
analysis of several cell lines with different antibodies.
The cell lines included in this study represent primary
melanomas with different growth patterns: RGP
(WM35, WM1552C, WM1575), VGP (WM278,
WM793B, WM902B, IGR39, WM115) and metastatic
melanomas derived from different sites (skin, lymph
nodes, visceral). Apart from two established cell lines,
IGR37 and WM266-4, all other metastatic melanoma
cells were of primary origin, isolated by mincing and
dissociating surgical biopsies and cultured in complete
medium. The melanoma origin of the cultures was pro-
ven by positivity to the S-100, HMB-45 and MART-1
staining (data not shown).
Cells were seeded on gelatin-coated multiwell-slides at
comparable densities (50-60% confluence), and different
antibodies were simultaneously hybridized to multiple
spots on the array (Figure 2). An affinity-purified poly-
clonal anti-PIR antibody was used to assess PIR expres-
sion. A polyclonal antibody recognizing the C-terminus
of the ShcA adaptor protein was used as control for
exclusive cytoplasmic localization, while anti-PIR total
serum and pre-immune serum were included in the
experiment as further controls. Signals were revealed
with Cy3 labelled goat anti-mouse or anti-rabbit second-
ary antibodies, and nuclei were stained with Diamino-2-
phenylindole (DAPI, Figure 3a, b). Image analysis was
performed using a specific freeware software (CellProfi-
ler) [20] to obtain fluorescence values corresponding to
nuclear and cytoplasmic staining for each single cell.
The average values of fluorescence for each antibody
were then calculated.
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For each cell line, the PIR fluorescent signal was quan-
tified cell-by-cell in the nucleus and in the cytoplasm.
The relative fraction of nuclear versus cytoplasmic signal
varied among the cell lines. On the contrary, the ShcA
signal, as expected, had a unique cytoplasmic localization
in all cell lines, thus providing a reliable reference in the
subsequent analysis. The cell lines included in the array
differ for morphology, size and level of PIR expression
(Figure 3a); in order to eliminate the influence of these
factors on the analysis of PIR distribution, for each cell
we normalized PIR and ShcA cytoplasmic fluorescence to
the total cellular fluorescence. Figure 3c shows the distri-
bution of PIR and ShcA normalized cytoplasmic signals
for all cell lines (higher values on the x-axis correspond
to higher intensities of cytoplasmic fluorescence). With
the exception of PIR signal in the WM1552 cell line, the
normalized cytoplasmic fluorescence signals are symme-
trically distributed across the populations. The cytoplas-
mic signals for ShcA are homogeneous among all cell
lines (both primary and metastatic cells) and are centred
on a mean value of 0.6, which we considered as a refer-
ence value for cytoplasmic protein localization. The dis-
tribution of PIR cytoplasmic signals are, instead, centred
on lower mean values: 0,4 in primary melanoma cell lines
and 0,5 in metastatic melanoma cell lines, suggesting that
there is on average a higher amount of cytoplasmic PIR
in metastatic melanoma cell lines, as previously observed
on TMA samples using IHC. In the case of the WM1552
cell line, we observed a bimodal distribution of PIR,
reflecting the presence of two subpopulations, one predo-
minantly cytoplasmic and one with a higher level of
nuclear localization. Comparable results were obtained
using total anti-PIR serum, compared to pre-immune
serum as a negative control (data not shown).
Figure 2 ICA antibody spotting scheme. Each cell line was plated
in one well of a 4-well slide; each antibody was spotted in 7
replicas on each well (see Methods for details)
Figure 1 Representative examples of PIR immunohistochemical staining in a melanoma-specific TMA. (a) Nuclear staining in normal
melanocytes (indicated by arrows) from a healthy skin tissue sample; (b) Primary infiltrating melanoma with low nuclear staining; (c) Mixed
nuclear and cytoplasmic staining in an intra-epidermal melanoma; (d) Intense staining both in the nucleus and in the cytoplasm in metastatic
melanoma; (e) strong exclusive cytoplasmic staining in metastatic melanoma. To detect immunoreactions VECTOR VIP was used as peroxidase
substrate in order to optimize differences between between the reaction product (purple) and background melanin. Original magnification 400×
for a, and 200× for b-e, scale bar 100 μm. Insets show 400× magnification. (f) Quantitative analysis of PIR subcellular distribution in the TMA
among Radial Growth Phase (RGP), Vertical Growth Phase (VGP) and Metastatic Melanoma (MM); Clark level is indicated.
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Figure 3 ICA results. Panels of ICA images showing (a) primary melanoma cell lines and (b) metastatic melanoma cell lines. Individual spots
were acquired with 20× objective: each image shows a representative area of one spot of the indicated antibody. (c) Analysis of ICA results (see
text for details) for primary melanoma cell lines; (d) analysis of ICA results for metastatic melanoma cell lines. Left panels refer to PIR normalized
cytoplasmic staining; right panels refer to ShcA normalized cytoplasmic staining. ShcA = anti-ShcA antibody; PIR IP = immuno-purified anti-PIR
antibody; PIR tot = anti-PIR total serum; P.I. = pre-immune serum.
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We next performed classical immunofluorescence (IF)
experiments on five cell lines included in the array, as a
validation of ICA results. PIR displayed a distinct
nuclear localization in two primary melanoma cell lines
tested, IGR39 and WM115 (Figure 4a, b respectively).
Among metastatic melanoma cell lines, AdMa1955 and
AnSe1935 displayed PIR staining predominantly in the
cytoplasm (Figure 4d, e respectively), while CaCi1962
presented mixed nuclear and cytoplasmic PIR staining
(Figure 4c). These results are in perfect agreement with
those obtained by ICA for the same cell lines and con-
firm the technical reliability of ICA technology. There-
fore, both techniques indicated a variable localization of
PIR protein in melanoma cell lines, and, in accordance
with IHC, suggest that a higher proportion of cytoplas-
mic PIR is characteristic of cell lines derived from more
advanced stages of melanoma progression. The number
of RGP and VGP samples analyzed by ICA is not suffi-
cient for the identification of significant differences
between the two categories; however, similarly to IHC,
the ICA approach revealed progressive shift of PIR loca-
lization towards the cytoplasm associated to disease pro-
gression. Among the cell lines of metastatic origin, we
did not find differences in localization associated to the
different sites of metastasis, suggesting that cytoplasmic
PIR may be a general characteristic of metastatic mela-
nomas. This is in agreement with data obtained on sur-
gical samples analyzed by IHC.
Conclusions
PIR is a multifunctional protein involved in different
and cellular processes, including transcription, apoptosis
and stress response, whose expression is modulated in
different types of human malignancies. In this report we
show that an abnormal pattern of PIR sub-cellular loca-
lization is a characteristic feature of a subset of melano-
mas, and suggest it may represent a marker associated
with disease progression. The pattern of PIR localization
observed by IHC in tumour samples is maintained in
cultured cell lines, both established and of primary deri-
vation, suggesting they represent a reliable model to
study the role of PIR in melanoma progression.
Furthermore, our study demonstrates that ICA tech-
nology allows for retrieval of reliable, high content infor-
mation and, simultaneously, for single cell analysis. ICA
is a low-cost and time saving approach, since it requires
small quantities of antibodies and allows for the analysis
of many cell lines at the same time using automated
procedures. The high level of consistency of ICA results
with IF data obtained on the same cell lines as well as
with IHC results obtained on primary melanoma sam-
ples represents an important validation of the power of
this novel technique for further applications.
Methods
Immunohistochemical analysis of primary melanoma
samples
Two melanoma-specific microarrays containing a total
of 135 primary melanomas and 61 metastatic melano-
mas were analyzed. Samples were provided by the
Pathology Departments of Istituto Europeo di Oncologia
(IEO, Milan) and Ospedale S. Paolo (HSP, Milan). Writ-
ten informed consent for research use of biological sam-
ples was obtained from all patients, and the research
project was approved by the IEO Institutional Ethical
Committee. Immunohistochemical staining was per-
formed overnight at +4°C with affinity-purified anti-PIR
antibody, followed by detection with VECTOR VIP (SK-
4600, Peroxidase substrate kit, Vector laboratories, Inc.
Burlingame, Ca 94010). For rabbit polyclonal anti-PIR
antibody production, EcoRI-SmaI digested PIR full
length coding sequence was inserted downstream to the
GST sequence in pGEX-4T1 vector (Pharmacia Biotech)
and the construct was transformed in BL21 strain of E.
coli to express GST-PIR fusion protein. After rabbit
immunization, total antiserum was antigen-purified and
eluted in PBS (0,01% BSA, 0,05% NaN3) at a concentra-
tion of 440 Ug/ml. For IHC the purified antibody was
used at a 1: 5 000 dilution in TBS (4% BSA, 0,02%
Tween20).
ImmunoCell-Arrays
Each cell line was plated in one well of a 4-well LabTe-
k™II slide (Nunc, Roskilde, Denmark). Cell lines analyzed
in this experiment were: WM1552C, WM1575, WM35,
WM278, WM793B, WM902B (provided by Dr Meen-
hard Herlyn, The Wistar Institute, Philadelphia) grown
in Tu2% medium (MCDB 153 Sigma Chemical Co., St.
Louis, MO) supplemented with L-15 (GIBCO Invitro-
gen), 5 μg/mL bovine insulin (Sigma Chemical), 2% fetal
bovine serum (FBS), and 1.68 mmol/L calcium chloride;
IGR39 and IGR37 (obtained from DSMZ, Braunschweig,
Germany) grown in DMEM (Lonza, Walkersville, MD)
supplemtented with 10% FBS; WM266-4 and WM115
(obtained from ATCC, Rockville, MD, USA) grown in
Eagle’s minimal essential medium (MEM, GIBCO Invi-
trogen) supplemented with 10% FBS, sodium pyruvate
and nonessential amino acids. AnSe1965, IrAv1938B,
CaCi1962, AdMa1935, LiGh1927B, ClVe1946 and
GaLa1949 were metastatic melanoma primary cell lines
established from surgical samples and grown in RPMI-
164 (Lonza, Walkersville, MD) supplemented with 10%
FBS.
Cells were plated to reach approximately 50-60% con-
fluence after 24 hours; after fixation, plastic walls of
LabTek slides were removed and cells were processed
according to ICA procedure [18,19]. Briefly, cell lines
were fixed with a solution of 4% paraformaldehyde in
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Figure 4 Validation of ICA results by conventional immunofluorescence. PIR subcellular localization pattern was confirmed by conventional
Immunofluorescence staining of melanoma cell lines with anti-PIR antibody detected with goat anti-rabbit Cy3. Left panels show PIR staining,
right panels show DAPI (63× oil objective magnification). (a) IGR39 (primary melanoma, nuclear staining); (b) WM115 (primary melanoma, nuclear
staining); (c) CaCi1962 (metastasis, mixed staining); (d) AdMa1935 (metastasis, cytoplasmic staining); (e) AnSe1965 (metastasis, cytoplasmic
staining). Insets show corresponding confocal images of representative cells (100× oil objective). Scale bar, 10 μm. Original greyscale images
were presented to avoid digital pseudocoloring with image editing softwares. PIR and DAPI images were kept separate due to overlapping
localization in some samples, and for correct visualization of PIR intensity in case of mixed localization in nuclei and cytoplasm.
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Pipes buffer (80 mM Pipes pH 6.8, 5 mM EGTA pH 8,
2 mM MgCl2) for 15 min. After fixation the slides were
washed twice with 1xPBS (Phosphate Buffer Saline) and
then permeabilized for 10 min with Triton 0.1% in a
solution of 1xPBS + 0.2% BSA, washed twice with
1xPBS, and blocked for 1 h with 2% BSA. After block-
ing, the slides were washed twice with 1xPBS and finally,
slides were drained to remove buffer in excess and
placed in the slide holder. The antibodies were dis-
pensed using a Biodot® BioJet Plus spotter with Axsys
software (BioDot Inc.): each antibody was spotted in 7
replicas on each well; 30 nl drops were spotted for each
antibody with a pitch of 1-2 mm, keeping during the
experiment uniform humidity at 65% in the spotting
chamber.
Primary antibodies were spotted and subsequently
incubated on the slide for 45 min at 4°C in 75% humid-
ity. After incubation, slides were washed twice with
1xPBS + 0,1% Tween, and 4 times in 1xPBS, drained as
above, and repositioned in the spotting chamber where
secondary antibodies were spotted. Secondary antibodies
were incubated as above for 30 min. After washing
twice in 1xPBS + 0.1% Tween, 4 times in 1xPBS, cells
were stained with DAPI for 5 min washed with 1xPBS,
H2O and mounted with Mowiol.
Antibodies used were: polyclonal affinity purified anti-
PIR; anti-ShcA C-20, sc-288 (purchased from Santa
Cruz Biotechnology, California, USA); polyclonal anti-
PIR total serum and corresponding pre-immune serum
as a negative control.
Conventional Immunofluorescence
Cells were grown on gelatin-coated glass coverslips,
fixed in 4% paraformaldehyde, washed and permeabi-
lized in PBS 0,1% Triton X-100. Pirin staining was per-
formed using polyclonal anti-PIR antibody followed by
treatment with Cy3-conjugated secondary anti-rabbit
antibody (Amersham). After extensive washes in PBS,
nuclei were stained for 5 minutes with DAPI (1:2000 in
PBS). Coverslips were mounted with Mowiol and exam-
ined with a Leica DMIR Fluorescence Microscope.
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